DK1608362T3 - Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse - Google Patents

Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse

Info

Publication number
DK1608362T3
DK1608362T3 DK03770970T DK03770970T DK1608362T3 DK 1608362 T3 DK1608362 T3 DK 1608362T3 DK 03770970 T DK03770970 T DK 03770970T DK 03770970 T DK03770970 T DK 03770970T DK 1608362 T3 DK1608362 T3 DK 1608362T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
composition containing
active compound
stabilized pharmaceutical
amorphous active
Prior art date
Application number
DK03770970T
Other languages
Danish (da)
English (en)
Inventor
Andrej Bastarda
Mateja Salobir
Rok Grahek
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32091984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1608362(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Application granted granted Critical
Publication of DK1608362T3 publication Critical patent/DK1608362T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK03770970T 2002-10-11 2003-10-10 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse DK1608362T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
PCT/EP2003/011265 WO2004032920A1 (en) 2002-10-11 2003-10-10 Stabilized pharmaceutical preparation comprising an amorphous active substance

Publications (1)

Publication Number Publication Date
DK1608362T3 true DK1608362T3 (da) 2007-05-14

Family

ID=32091984

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03770970T DK1608362T3 (da) 2002-10-11 2003-10-10 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse
DK200700025U DK200700025U4 (da) 2002-10-11 2007-01-25 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK200700025U DK200700025U4 (da) 2002-10-11 2007-01-25 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse

Country Status (21)

Country Link
US (2) US20040077708A1 (ru)
EP (1) EP1608362B1 (ru)
CN (1) CN100372529C (ru)
AR (1) AR041588A1 (ru)
AT (2) ATE354362T1 (ru)
AU (1) AU2003280361B2 (ru)
CY (1) CY1106608T1 (ru)
CZ (1) CZ17610U1 (ru)
DE (2) DE60312049T2 (ru)
DK (2) DK1608362T3 (ru)
ES (1) ES2285205T3 (ru)
FI (1) FI7617U1 (ru)
ME (1) ME00514B (ru)
PT (1) PT1608362E (ru)
RS (1) RS51819B (ru)
RU (1) RU2358727C2 (ru)
SI (2) SI21302A (ru)
SK (1) SK5233Y1 (ru)
TW (1) TWI320709B (ru)
UA (1) UA85544C2 (ru)
WO (1) WO2004032920A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US8777011B2 (en) 2001-12-21 2014-07-15 Novartis Ag Capsule package with moisture barrier
EP1653930B1 (en) * 2003-08-05 2007-12-19 Zentiva, a.s. Methods for the stabilization of atorvastatin
EP1577297A1 (en) * 2004-03-17 2005-09-21 Ranbaxy Laboratories, Ltd. Process for the production of atorvastatin calcium in amorphous form
JP5000502B2 (ja) * 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
JP2008514722A (ja) * 2004-09-30 2008-05-08 ドクター レディズ ラボラトリーズ リミテッド 非結晶性アトルバスタチンカルシウム
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (en) * 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
US20090071855A1 (en) * 2007-09-14 2009-03-19 Bahuguna Sumit Packaging for amorphous statins and compositions thereof
EP2127628A1 (en) * 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Unit dose pack
KR20120128599A (ko) 2009-12-25 2012-11-27 사와이세이야쿠 가부시키가이샤 아트로바스타틴 함유 피복 제제
EP2779999A2 (en) 2011-11-15 2014-09-24 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法
CN107530311A (zh) * 2015-02-03 2018-01-02 卡德门制药有限公司 稳定的曲恩汀制剂
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
US11968975B2 (en) 2019-04-30 2024-04-30 Regents Of The University Of Minnesota Compositions and methods for storing liquid biospecimens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2194418B2 (ru) * 1971-08-02 1977-01-28 Sada Pietro
DE2625164A1 (de) * 1976-06-04 1977-12-15 Goedecke Ag Fluessige oder halbfeste arzneiformen oder kosmetische zubereitungen
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE69506122D1 (de) * 1994-09-30 1998-12-24 Becton Dickinson Co Verfahren zur herstellung und verpackung von iontophoretischen pflastern und denselben, um die stabilität und die lagerstabilität zu verbessern
GB9425783D0 (en) * 1994-12-21 1995-02-22 Ethical Pharma Ltd Packaging of patches
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
SG125044A1 (en) * 1996-10-14 2006-09-29 Mitsubishi Gas Chemical Co Oxygen absorption composition
US6155454A (en) * 1997-05-03 2000-12-05 Donald C. George Pill dispenser employing a sealed pill carrier and integrated dispensing plungers
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6375956B1 (en) * 1999-07-22 2002-04-23 Drugtech Corporation Strip pack
ATE418979T2 (de) * 2000-06-09 2009-01-15 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
US6293393B1 (en) * 2000-07-18 2001-09-25 Sdk Co., Inc. Apparatus and methods for packaging and distributing combinations of foods and beverages
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1241110A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs

Also Published As

Publication number Publication date
DK200700025U1 (da) 2007-06-08
FIU20070036U0 (fi) 2007-01-26
PT1608362E (pt) 2007-05-31
US20090012150A1 (en) 2009-01-08
DE20321455U1 (de) 2007-05-24
DE60312049T2 (de) 2007-10-04
EP1608362B1 (en) 2007-02-21
WO2004032920A1 (en) 2004-04-22
AU2003280361B2 (en) 2009-02-26
ME00514B (me) 2011-10-10
SK50062007U1 (en) 2009-03-05
FI7617U1 (fi) 2007-09-28
CN100372529C (zh) 2008-03-05
CZ17610U1 (cs) 2007-06-18
AR041588A1 (es) 2005-05-26
SI1608362T1 (sl) 2007-12-31
EP1608362A1 (en) 2005-12-28
UA85544C2 (ru) 2009-02-10
SI21302A (sl) 2004-04-30
DE60312049D1 (de) 2007-04-05
AU2003280361A1 (en) 2004-05-04
RS51819B (sr) 2011-12-31
AT10424U1 (de) 2009-03-15
RS20050273A (en) 2007-06-04
RU2005114485A (ru) 2006-01-27
SK5233Y1 (en) 2009-09-07
TW200501947A (en) 2005-01-16
CY1106608T1 (el) 2012-01-25
US20040077708A1 (en) 2004-04-22
TWI320709B (en) 2010-02-21
DK200700025U4 (da) 2008-03-14
CN1703215A (zh) 2005-11-30
RU2358727C2 (ru) 2009-06-20
ATE354362T1 (de) 2007-03-15
ES2285205T3 (es) 2007-11-16

Similar Documents

Publication Publication Date Title
DK1608362T3 (da) Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
DE50309032D1 (de) Fungizide wirkstoffkombinationen
PT1501534E (pt) Formulacoes farmaceuticas
IL162118A0 (en) Pharmaceutical compositions containing an orally active taxane derivative
DE60317967D1 (de) Umhüllte feste Darreichungsform
DK1558585T3 (da) Neurologisk aktive forbindelser
EP1631239A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE COMPOUNDS OF VITAMIN D
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
FI20031078A0 (fi) Antibioottisesti oletiivisia farmaseuttisia koostumuksia
DK1666473T3 (da) Carboxylsyreforbindelser og medicinske sammensætninger indeholdende samme som aktiv ingrediens
ITFI20020144A1 (it) Formulazioni topiche stabilizzate contenenti ketoprofene.
AU2003291642A1 (en) Pyrazoloazepine compounds as pharmaceutical agents
ITTO20020672A1 (it) Composizioni farmaceutiche contenenti cheto-acidi per somministrazione endoperitoneale
DE502004003170D1 (de) Schmelzformulierte, multipartikuläre orale darreichungsform enthaltend clavulansäure
IL172304A0 (en) Pharmaceutical compositions comprising active vitamin d compounds
AU2003238896A1 (en) Stabilized pharmaceutical compositions containing benzimidazole compounds
ITMI20011457A0 (it) Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
NO20044164L (no) Farmasoytiske sammensetninger
AU2003240741A1 (en) Calixarenes for use as excipient for an active substance
NO20025959D0 (no) Dispenser for tanntråd
ITMI20020639A1 (it) Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
SE0201660D0 (sv) Pharmaceutical formulation
SE0200449D0 (sv) Pharmaceutical formulation